Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of CBP-307 on QTc Interval in Healthy Subjects
NCT04818229Phase 1Completed
- Sponsor
- Connect Biopharma
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of icanbelimod in ulcerative colitis (UC) and Crohn's disease (3 arms), sponsored by Connect Biopharma. Primary endpoint: Change-from-baseline QT Interval Corrected for Heart Rate Using Fridericia's Method at Day 16. Started Jun 2021; status: completed.
02
Drugs
icanbelimod
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04818229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818229.